NIH Establishes Office To Probe Science Misconduct

WASHINGTON—If NIH is the crown jewel of federal biomedical research, then scientific misconduct is a scratch on its surface. And Brian Kimes is the man that NIH officials hope will begin to restore the luster their organization has lost in the eyes of Congress and the public. On April 10 Kimes became acting director of the newly formed Office of Scientific Integrity (OSI). The office was created by officials within the Public Health Service, NIH’s parent agency, as part of a two-

Written byJeffrey Mervis
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

WASHINGTON—If NIH is the crown jewel of federal biomedical research, then scientific misconduct is a scratch on its surface. And Brian Kimes is the man that NIH officials hope will begin to restore the luster their organization has lost in the eyes of Congress and the public.

On April 10 Kimes became acting director of the newly formed Office of Scientific Integrity (OSI). The office was created by officials within the Public Health Service, NIH’s parent agency, as part of a two-step process to deal with misconduct in all programs funded by the agency. It will take over many of the duties now performed by the beleaguered institutional liaison office headed by Janet Newburgh.

Agency officials hope that the new mechanism will convince Congress that NIH is capable of rooting out, and ultimately preventing, most cases of misconduct by scientists. Its duties, as spelled out in the March 18 Federal ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies